Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis |
journalArticle |
2017 |
Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y. |
Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy |
journalArticle |
2017 |
Annede, P.; Seisen, T.; Klotz, C.; Mazeron, R.; Maroun, P.; Petit, C.; Deutsch, E.; Bossi, A.; Haie-Meder, C.; Chargari, C.; Blanchard, P. |
Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow |
journalArticle |
2017 |
Blanchard, P.; Menard, C.; Frank, S. J. |
Enjeux méthodologiques de la médecine de précision en oncologie |
journalArticle |
2017 |
Asselain, B.; Paoletti, X. |
Letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?" |
journalArticle |
2017 |
Hill, C.; Asselain, B. |
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study |
journalArticle |
2017 |
Bredart, A.; Bodson, S.; Le Tourneau, C.; Flahault, C.; Bonnetain, F.; Beaudeau, A.; Coquan, E.; Dolbeault, S.; Paoletti, X. |
Statistical approaches for evaluating body composition markers in clinical cancer research |
journalArticle |
2017 |
Bayar, M. A.; Antoun, S.; Lanoy, E. |
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification |
journalArticle |
2017 |
Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J. |
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials |
journalArticle |
2017 |
Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F. |
[Proton therapy for head and neck cancers] |
journalArticle |
2017 |
Blanchard, P.; Frank, S. J. |
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study |
journalArticle |
2017 |
Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L. |
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis |
journalArticle |
2017 |
Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y. |
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice |
journalArticle |
2017 |
Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M. |
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification |
journalArticle |
2017 |
Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J. |
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors |
journalArticle |
2017 |
Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C. |
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial |
journalArticle |
2017 |
Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V. |
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study |
journalArticle |
2017 |
Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S. |
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? |
journalArticle |
2017 |
Blanchard, P.; Bossi, A.; Fizazi, K. |
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials |
journalArticle |
2017 |
Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F. |
The frequency of cancer in France: Most recent data and trends |
journalArticle |
2017 |
Ribassin-Majed, L.; Le-Teuff, G.; Hill, C. |
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial |
journalArticle |
2017 |
Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C. |
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients |
journalArticle |
2017 |
Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C. |
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study |
journalArticle |
2017 |
Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A. |
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? |
journalArticle |
2017 |
Blanchard, P.; Bossi, A.; Fizazi, K. |
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? |
journalArticle |
2017 |
Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S. |
In Regard to Arthurs et al |
journalArticle |
2017 |
Blanchard, P.; Garden, A. S. |
Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma |
journalArticle |
2017 |
Conversano, A.; Mazouni, C.; Thomin, A.; Gaudin, A.; Fournier, M.; Rimareix, F.; Bonastre, J. |
Impact of dermatologic adverse events induced by targeted therapies on quality of life |
journalArticle |
2016 |
Charles, C.; Bungener, C.; Razavi, D.; Mateus, C.; Routier, E.; Lanoy, E.; Verschoore, M.; Robert, C.; Dauchy, S. |
Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01) |
journalArticle |
2016 |
Tacher, V.; Le Deley, M. C.; Hollebecque, A.; Deschamps, F.; Vielh, P.; Hakime, A.; Ileana, E.; Abedi-Ardekani, B.; Charpy, C.; Massard, C.; Rosellini, S.; Gajda, D.; Celebic, A.; Ferte, C.; Ngo-Camus, M.; Gouissem, S.; Koubi-Pick, V.; Andre, F.; Vassal, G.; Deandreis, D.; Lacroix, L.; Soria, J. C.; De Baere, T. |
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer |
journalArticle |
2016 |
Michiels, S.; Pugliano, L.; Marguet, S.; Grun, D.; Barinoff, J.; Cameron, D.; Cobleigh, M.; Di Leo, A.; Johnston, S.; Gasparini, G.; Kaufman, B.; Marty, M.; Nekljudova, V.; Paluch-Shimon, S.; Penault-Llorca, F.; Slamon, D.; Vogel, C.; von Minckwitz, G.; Buyse, M.; Piccart, M. |
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours |
journalArticle |
2016 |
Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K. |
MRI-guided brachytherapy in locally advanced cervical cancer: Small bowel [Formula: see text] and [Formula: see text] are not predictive of late morbidity |
journalArticle |
2016 |
Petit, C.; Dumas, I.; Chargari, C.; Martinetti, F.; Maroun, P.; Doyeux, K.; Tailleur, A.; Haie-Meder, C.; Mazeron, R. |
Treatment of squamous cell carcinoma of the posterior pharyngeal wall: Radiotherapy versus surgery |
journalArticle |
2016 |
De Felice, F.; Blanchard, P.; Levy, A.; Nguyen, F.; Gorphe, P.; Janot, F.; Temam, S.; Tao, Y. |
New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues |
journalArticle |
2016 |
Martelli, N.; van den Brink, H.; Borget, I. |
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial |
journalArticle |
2016 |
Blanchard, P.; Faivre, L.; Lesaunier, F.; Salem, N.; Mesgouez-Nebout, N.; Deniau-Alexandre, E.; Rolland, F.; Ferrero, J. M.; Houede, N.; Mourey, L.; Theodore, C.; Krakowski, I.; Berdah, J. F.; Baciuchka, M.; Laguerre, B.; Davin, J. L.; Habibian, M.; Culine, S.; Laplanche, A.; Fizazi, K. |
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence |
journalArticle |
2016 |
Ignatiadis, M.; Azim, H. A.; Desmedt, C.; Veys, I.; Larsimont, D.; Salgado, R.; Lyng, M. B.; Viale, G.; Leyland-Jones, B.; Giobbie-Hurder, A.; Kammler, R.; Dell'Orto, P.; Rothe, F.; Laios, I.; Ditzel, H. J.; Regan, M. M.; Piccart, M.; Michiels, S.; Sotiriou, C. |
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence |
journalArticle |
2016 |
Ignatiadis, M.; Azim, H. A.; Desmedt, C.; Veys, I.; Larsimont, D.; Salgado, R.; Lyng, M. B.; Viale, G.; Leyland-Jones, B.; Giobbie-Hurder, A.; Kammler, R.; Dell'Orto, P.; Rothe, F.; Laios, I.; Ditzel, H. J.; Regan, M. M.; Piccart, M.; Michiels, S.; Sotiriou, C. |
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination |
journalArticle |
2016 |
Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F. L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A. M.; Soria, J. C.; Mateus, C.; Robert, C. |